precision oncology

Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…

From crowded oncology wards in Cairo to international leadership in cancer education, Dr. Mohamed Emam Sobeih has built a career shaped by one central belief: treating cancer requires more than medicine alone. At the National Cancer Institute Egypt, where Dr…

Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…

As cancer survival improves, a critical gap persists: the period after treatment, where psychological distress, identity disruption, and unmet needs remain insufficiently addressed in routine oncology care. A System Designed for Treatment, Not Transition “We have to be next to…

In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…

In oncology, some ideas arrive too early. For decades, cancer vaccines were one of them. The concept was elegant: train the immune system to recognise tumour cells, much like it recognises viruses, and allow it to eliminate disease with precision…

In the quieter corners of European health policy, where attention is often fragmented and political capital fiercely contested, pancreatic cancer has long remained an uncomfortable outlier—aggressive, difficult to detect, and historically underprioritised. Yet, as Europe confronts an evolving cancer burden,…

Many people diagnosed with cancer often wonder what “caused” their disease and whether they could have done anything to prevent it. Typically, the risk of developing cancer is determined by a combination of genetics and environmental exposures, causing errors in…

Imagine an oncologist stepping out of tumor board and into clinic with a complex case at hand. The patient’s tumor has multiple high-risk features, genomic mutations, and borderline indications for therapy. In the past, the doctor might sift through guidelines,…

It was 2018, and I was a fifth-year medical student at Yerevan State Medical University. Word spread that our new oncology professor was someone extraordinary: Gevorg Tamamyan - a Harvard-trained, Nature-published pioneer of pediatric oncology in Armenia and president of…